Condition: Symptomatic Chronic Middle Cerebral Artery Occlusion · Infarction, Middle Cerebral Artery · Sponsor: Xuanwu Hospital, Beijing
The CMOSS-2 trial is a government-funded, prospective, multicenter, randomized controlled trial. It will recruit symptomatic chronic occlusion of the middle cerebral artery in patients with severe hemodynamic insufficiency. Only high-volume center with a proven track record will be included. Patients will be randomized (1:1) to best medical treatment alone or medical treatment plus bypass surgery. Primary outcome is ischemic stroke in the territory of the target artery within 24 months after randomization.
This description comes directly from the study's public registry record.
Yan Ma, MD · 13810669502 · leavesyan@sina.com
Tao Wang, MD · 18810302298 · wangtao_dr@sina.com
Always discuss trial participation with your own doctor first.
| Xuanwu Hospital, Capital Medical University. | Beijing, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05899582